Black Diamond Therapeutics Q2 net loss narrows as costs drop

Black Diamond Therapeutics

07/08/2025 13:02

Overview

Black Diamond Q2 net loss narrows to $10.6 mln from $19.9 mln yr/yr

Exploring partnerships to advance silevertinib development in NSCLC and GBM

Outlook

Black Diamond expects Q4 2025 data release for silevertinib Phase 2 trial

Company plans FDA meeting in 1H 2026 for silevertinib NSCLC path

Black Diamond exploring partnerships for silevertinib pivotal development

Company sees cash funding operations into Q4 2027

Result Drivers

EXPENSE REDUCTION - Reduced R&D and G&A expenses due to workforce efficiencies and restructuring

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Net Income
-$10.56 mln
Q2 Basic EPS
-$0.19
Q2 Cash & Investments
$142.80 mln
Q2 Income From Operations
-$13.42 mln
Q2 Operating Expenses
$13.42 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Black Diamond Therapeutics Inc is $11.00, about 75.5% above its August 6 closing price of $2.69

Press Release: ID:nGNX3VLXy8

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)